Clinical Trial Update: A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating changes in FDG- and FLT-PET imaging in non-small cell lung cancer after erlotinib treatment, with results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Genentech, Inc. | Conditions: Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2011-10-03